Way back in the day Starpharma owned 30% of Dimerix
11 May 2005 INVESTEE COMPANY DIMERIX BIOSCIENCE OFFERED AUSINDUSTRY GRANT
Dimerix Bioscience Pty Ltd (“Dimerix”, an investee company of Starpharma Holdings Ltd (ASX:SPL, USOTC:SPHRY) has announced its success in securing a $200,000 'Commercial Ready' grant by AusIndustry to support the development of a new class of drugs targeting G-protein Coupled Receptors (GPCRs).
Starpharma is the largest shareholder in Dimerix, with a 30% equity holding. Starpharma has also entered into a joint venture with Dimerix focused on dendrimer based GPCR drug discovery and development, utilising the Dimerix Collision technology. Starpharma CEO Dr John Raff said: “Starpharma is confident that the Dimerix receptor coupling technology will lead to the development of new classes of pharmaceutical drugs. We are pleased that AusIndustry has also recognised the potential of this company’s technology.”
Oh I wish they had held
DXB Price at posting:
77.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
, an investee company of Starpharma Holdings Ltd (ASX:SPL, USOTC:SPHRY) has announced its success in securing a $200,000 'Commercial Ready' grant by AusIndustry to support the development of a new class of drugs targeting G-protein Coupled Receptors (GPCRs).
(20min delay)